Rivastone Capsule 1.5 mg (Rivastigmine Tartrate)

Adult dose

Administration: Rivastigmine is administered orally twice daily with the morning and evening meals. ○ Adults: 1. Treatment of mild to moderate Alzheimer's dementia The initial dose is 3 mg of rivastigmine daily. For each patient, increase the dose at intervals of at least 2 weeks to the highest tolerated dose or the maximum recommended dose of 12 mg daily. Because this drug showed greater efficacy in clinical trials at doses of 6 mg daily and above, a target dose range of 6~12 mg daily is recommended for most patients. Recommended dose titration Administer this drug at 1.5 mg per dose twice daily for at least 2 weeks. If well tolerated, the dose may be increased to 3 mg twice daily. For subsequent increases, administer 4.5 mg per dose twice daily; if well tolerated, after at least 2 weeks increase to 6 mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite) or weight loss are observed, one or more doses may be omitted. However, if adverse reactions or weight loss persist, reduce the daily dose to the dose that was previously well tolerated. 2. Treatment of mild to moderate dementia associated with Parkinson's disease In a controlled clinical trial in patients with dementia associated with Parkinson's disease, rivastigmine was administered at 3~12 mg daily in 2 divided doses (1.5~6 mg per dose twice daily). The initial dose is 1.5 mg per dose twice daily. At intervals of at least 4 weeks between dose levels, and according to patient tolerability, the dose may be increased in sequence to 3 mg per dose twice daily, then 4.5 mg per dose twice daily, and subsequently 6 mg per dose twice daily. If adverse reactions (e.g., nausea, vomiting, abdominal pain, or decreased appetite), weight gain, or extrapyramidal symptoms (e.g., tremor) are observed during treatment, withholding one or more doses may reduce these symptoms. If adverse reactions persist, temporarily reduce the daily dose to the dose previously well tolerated or consider discontinuing treatment. 3. Maximum recommended dose Administer 6 mg of this drug per dose orally twice daily. 4. Resumption of treatment The frequency and severity of adverse reactions generally increase at higher doses. If treatment is interrupted for 3 days or longer, restart at the lowest daily dose and titrate as described above. ○ Patients with hepatic or renal impairment: 1. Exposure is increased in patients with moderate renal impairment and mild to moderate hepatic impairment, and more adverse reactions may occur. Therefore, take particular care when titrating the dose according to individual tolerability. 2. Do not administer to patients with severe hepatic impairment, as studies have not been conducted in these patients.

Child dose

This drug has not been studied in children; therefore, its use in children is not recommended.

This medication should not be used in patients with allergies to specific ingredients or severe liver disorders. Patients with heart disease, peptic ulcers, asthma, obstructive pulmonary disease, urinary obstruction, seizures, or extrapyramidal disorders should use this medication cautiously. Gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur at the start of treatment or when the dosage is increased, so caution is advised. This medication can slow heart rate, so patients with heart-related conditions should use it under a physician's direction. Caution is advised as this medication may worsen symptoms in patients with asthma or obstructive pulmonary disease. Weight loss may occur during treatment, making regular weight monitoring important. Drowsiness and dizziness may occur, requiring caution when driving or operating machinery. The safety of this medication during pregnancy or breastfeeding has not been established, so consultation with a physician is necessary before use. Interactions with other medications may occur, so patients should inform of any other medications being taken. In cases of overdose, symptoms such as nausea, vomiting, dizziness, and bradycardia may arise, which necessitates immediate medical attention. This medication is not recommended for children. When using this medication, it should be stored out of reach of children, and it is advisable not to transfer it into other containers.

• Area
• vomiting
• dizziness
• headache
• drowsiness
• tremor
• syncope
• convulsion
• extrapyramidal symptoms
• angina pectoris

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is best stored at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.

Appearance

A hard capsule with a white to yellowish powder inside, yellow in color at the lower part.

Package unit

28 capsules/box [14 capsules/PTP×2]